Adverum is a gene therapy company advancing novel medicines that may offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.
Adverum Biotechnologies NASDAQ:
10/20/17 1:20 AM EDT
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Oct 2 2017
Summary ToggleAdverum Biotechnologies Appoints Linda Neuman, M.D. as Vice President, Clinical Development
- Sep 28 2017
Summary ToggleAdverum Biotechnologies to Present at Upcoming Conferences
- Sep 27 2017
Summary ToggleAdverum Biotechnologies Presents Updated Preclinical Data on ADVM-022 in Wet AMD at the 2017 Targeting Ocular Disorders Conference
- Sep 7 2017
Summary ToggleAdverum Biotechnologies Appoints Eric G. Carter, M.D., Ph.D. to Board of Directors